Session Coverage

Though well-studied in general, pulmonary arterial hypertension (PAH) presents specific challenges in diagnosis and response in a critical care environment, said Farah Kazzaz, MD.

As clinicians increasingly care for patients with complex comorbidities, managing TB has become far more nuanced than simply prescribing a standard treatment regimen, said Sebastian Kurz, MD, PhD, FCCP.

Advancements in thoracic ultrasonography are transforming clinicians’ day-to-day decision-making, said Labib G. Debiane, MD, MS, FCCP.

Presenters will review the latest research and clinical case studies to better equip clinicians in tailoring effective cessation strategies for youth and young adults, said Frank Leone, MD, MS, FCCP.

In central sleep apnea (CSA) care, clinicians are increasingly asked to move beyond one-size-fits-all approaches and toward phenotype-driven, patient-centered care, said Timothy I. Morgenthaler, MD, FCCP.

The treatment landscape for interstitial lung diseases (ILDs) has expanded dramatically in recent years, creating new opportunities—and new challenges—for clinicians, said Sean J. Callahan, MD, FCCP.

Biologics and antialarmins are rewriting the playbook for COPD treatment and opening the field to more targeted therapies and precision medicine, said Sara Assaf, MD.

The session will guide attendees through complex pneumothorax decision-making and explore cases from the audience, said Laura Kathleen Frye, MD, FCCP.

Other major topics of discussion will include endemic infections, rare-but-deadly pulmonary pathogens, and changes in vaccine policy, said Ryan Maves, MD, FCCP.

Sessions will look at new information about patients who are receiving glucagon-like peptide-1 (GLP-1) medications and how that affects their sleep-disordered breathing, said Sherri Katz, MD, FCCP.